Jacob Borodovsky
Dartmouth College, NH·Public Health & Epidemiology
Legal cannabis is now widely used and widely marketed in the United States, often as a remedy for pain, anxiety or depression. Yet the rules for regulating its marketing and the criteria for diagnosing problem use have not kept pace.
- Fields
Public Health & Epidemiology
Psychology
Medicine & Clinical Research
- Topics
cannabis
marijuana
chronic pain
- Grants
- 2 known grants, through Jan 2031
What they work on
- Test whether psychotherapeutic advertising claims, ads saying cannabis treats anxiety or depression, increase THC purchased by users with depression or anxiety, by randomizing 2,000 shoppers across four versions of a simulated online dispensary.
- Determine whether mental health warning labels reduce the effect of those advertising claims on total THC milligrams, product potency and number of products selected.
- Survey 1,000 daily cannabis users with chronic pain about efforts to obtain medical supervision and dose information, to create guidelines separating therapeutic from other cannabis use.
- Adapt an opioid diagnostic interview into PRISM-CUD and compare reliability and validity of unadjusted, physiologically adjusted and therapeutically adjusted cannabis use disorder models in 3,000 online participants.
More about the research
Two projects approach this gap from different sides: one asks how mental-health advertising claims shape what people buy, the other asks how clinicians should tell medical use apart from cannabis use disorder (CUD), a diagnosable pattern of harmful use.
Why it matters
Findings could inform cannabis advertising rules that protect people with depression or anxiety from misleading mental-health claims, which may increase use and worsen symptoms. Improved cannabis use disorder criteria for chronic pain patients could sharpen treatment referrals, clinical trial eligibility, prevalence estimates and clinician training, and may inform future revisions of psychiatric diagnostic manuals.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Leah Ranney
University of North Carolina at Chapel Hill, NC·Public Health & Epidemiology
Examine the legal and regulatory landscape of U.S. cannabis warning labels, through a comprehensive legal analysis and key informant interviews with state cannabis regulators.
Christian Hopfer
University of Colorado Denver/Anschutz Medical Campus, CO·Medicine & Clinical Research
Test whether 8 weeks of hemp-derived cannabidiol (CBD), compared with placebo, reduces THC use, cannabis use disorder symptoms, anxiety and depression in emerging adults who use cannabis regularly, using a randomized trial.
Elise Weerts
Johns Hopkins University, MD·Pharmacology
Test whether vaporized cannabis extract produces effects that rats trained on injected THC recognize as similar, and whether a CB1 receptor blocker cancels them, using drug discrimination procedures.
The school
Dartmouth College: 16 labs on PI Pages, $418M a year on research, 104 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.